Biomedical Engineering Reference
In-Depth Information
ability fi lters and models for bioactivity. Individual research groups or founda-
tions could be alerted if a molecule matching their desired criteria is submitted.
The platform will then prompt whoever has opted in and has appropriate
privileges to set up a collaboration between the parties involved and to prepare
any legal confi dential disclosure agreements (CDAs), for example, prior to
receipt of the physical molecule, to arrangement for purchase, to synthesis, or
to screening.
21.6
FUTURE DIRECTIONS OF CDD DATABASE
In the future we propose that Web 2.0 technology [24] will enable researchers
that “opt in” to be made aware of other potential researchers with similar
interests or similar compounds or vendors with similar compounds. We will
also facilitate the linkage between academic and foundation researchers with
a network of experienced medicinal chemistry, cheminformatics, and absorp-
tion, distribution, metabolism, excretion, and toxicity (ADME/Tox) collabora-
tors or consultants who can assist them with advancing their compounds
further. In this way CDD could become a central marketplace for collabora-
tion and research in much the same way that www.assaydepot.com provides
a convenient central location for clinical research organizations (CROs).
21.6.1
How to Build (Neglected) Disease Communities on the Cloud
(i)
Capture and Curate Large Amounts of Disease Assay Data Points
Compound structures can be readily harvested from the most relevant
scientifi c journals, patents, and other available published sources pref-
erably using manual and a combination of natural language processing
and manual curation. Provide these data as a public-access read-only
resource to benefi t all researchers (community member/subscribers
would be able to download any public data set).
(ii)
Data Resulting from Different Disease Research Projects Are Archived
in CDD Database
To enhance and accelerate discovery research col-
laborations throughout the network (with the requisite incentives to
collaborate while always giving data generators the choice). CDD
generally starts with several key seed groups of researchers that pledge
participation—generally prominent disease researchers and drug dis-
covery groups.
(iii)
Work with CDD Members to Identify Collaborative Research Oppor-
tunities within Network and Support Integration of New Networked
Members ' Research Efforts
CDD scientifi c consultants aid in build-
ing collaborations around the following drug discovery cycle compo-
nents: (1) model building, (2) data mining and virtual screening, (3)
compound procurement, (4) compound profi ling, and (5) research data
interpretation.
Search WWH ::
Custom Search